July 11, 2025 08:00 AM EDTUpdated 11:29 AM

As researchers come together for HIV conference, few biotechs can stay the course

Kyle LaHucik

Biotech Correspondent

A key delegation of HIV researchers, public health experts and drug developers will come together next week in Rwanda for the biennial International AIDS Society …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

As researchers come together for HIV conference, few biotechs can stay the course

Kyle LaHucik

Biotech Correspondent

Sign up to read this article for free.

FDA's Makary calls for tying fast-review vouchers to lower US prices, without specifics

Sally Susman waves goodbye to Pfizer; Xaira's new president and COO

Karyopharm cuts 20% of staff as it looks at 'strategic alternatives' or raising cash

FDA hands Capricor a CRL for its Duchenne cell therapy

Biotech’s Q2 numbers paint a picture of the good, the bad and the ugly

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases

As re­searchers come to­geth­er for HIV con­fer­ence, few biotechs can stay the course

Kyle LaHucik

Biotech Correspondent

Sign up to read this article for free.

FDA's Makary calls for ty­ing fast-re­view vouch­ers to low­er US prices, with­out specifics

Sal­ly Sus­man waves good­bye to Pfiz­er; Xaira's new pres­i­dent and COO

Karyopharm cuts 20% of staff as it looks at 's­trate­gic al­ter­na­tives' or rais­ing cash

FDA hands Capri­cor a CRL for its Duchenne cell ther­a­py

Biotech’s Q2 num­bers paint a pic­ture of the good, the bad and the ug­ly

Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

As researchers come together for HIV conference, few biotechs can stay the course

FDA's Makary calls for tying fast-review vouchers to lower US prices, without specifics

Sally Susman waves goodbye to Pfizer; Xaira's new president and COO

Karyopharm cuts 20% of staff as it looks at 'strategic alternatives' or raising cash

FDA hands Capricor a CRL for its Duchenne cell therapy

Biotech’s Q2 numbers paint a picture of the good, the bad and the ugly

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases